Science News from #ISC26
Sessions: February 4–6, 2026
Ernest N. Morial Convention Center | New Orleans, Louisiana
Understand the science from #ISC26
Dive into the details of the most exciting Late-breaking science presented during the International Stroke Conference 2026. Starting on Wednesday, Feb. 3, 2026, you'll find links to video interviews with presenting investigators and American Heart Association professional volunteers, along with data summaries and conclusions.
Find all of the content you need right here.
2026 Important Links
Programming
- #ISC26 Abstracts in Stroke – Science abstracts (except Late-Breaking Science)
- Articles published Simultaneously in AHA Journals
- 2026 Online Program Planner site – Abstracts, schedules, and more
- Late-Breaking Science – Top trial results
- Virtual Programming – Watch or rewatch sessions
- CE Credit – Instructions on how to claim credit
- ISC 2026 ePosters (sign in with conference badge number) and historical ISC ePosters
While On-Site
- For Presenters & Moderators – details and how-to instructions
- Mobile Meeting Guide App ‐ #ISC26 on your phone
- American Heart Association Newsroom – news releases
- #ISC26 Science News – in-depth interviews with presenting investigators, data slides
- ISC Conference Coverage
- ISC Daily News (newspaper)
Guidelines and references
CHOICE-2
The Chemical Optimization of Cerebral Embolectomy Trial: Main Results
Angel Chamorro | Hospital Clinic Barcelona, Barcelona, Spain
RESULTS: Intra-arterial alteplase following successful thrombectomy was associated with increased rates of excellent functional outcome, supporting its use in appropriately selected patients.
FASTEST
Recombinant Factor VIIa for Spontaneous Intracerebral Hemorrhage within Two Hours of Onset
Joseph P Broderick | University of Cincinnati, Cincinnati, OH
RESULTS: rFVIIa slowed growth of hematoma when administered within 2 hours of ICH symptom onset in patients with a spot sign but had slightly increased risk for life-threatening thromboembolic complications and did not improve overall functional outcomes when compared to placebo.
CREST-2
The Effect of Treatment on Cognitive Function in Patients with Asymptomatic Carotid Artery Stenosis
Ronald M Lazar | University of Alabama at Birmingham, Birmingham, AL
RESULTS: Neither the addition of CAS nor CEA demonstrated cognitive benefit compared to IMM alone, including in patients with worse baseline cognition.
Day One Highlights
Lauren Sansing, MD, MS, FAHA, Chair of the International Stroke Conference, and Bijoy Menon, MBBS, MD, Msc, FRCPC, Vice-Chair, discuss the results of some of the Late-breaking Science presented in Wednesday's Opening Event.
Maternal Stroke: A Survivor's Story
Eliza C. Miller, MD, MS, writing group chair for a new scientific statement on maternal stroke, interviews Erin Adelekun, "Stroke Mama," about her experience as a maternal stroke survivor.
Follow Erin on Instagram at @strokemama.
OCEANIC-STROKE
Factor XIa Inhibition with Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial
Mukul Sharma, MD, MSc | Population Health Research Institute (ONT)
RESULTS: Asundexian was associated with a reduced occurrence of ischemic stroke in patients with non-cardioembolic ischemic stroke or high-risk TIA receiving antiplatelet therapy, without an increase in major bleeding compared with placebo.
EMBOLISE
Embolization of the Middle Meningeal Artery with ONYXTM Liquid Embolic System In the Treatment of Subacute and Chronic Subdural Hematoma
Jared Knopman | Weill Cornell Medical College
RESULTS: Middle Meningeal Artery (MMA) embolization with Onyx™ was superior to observation in reducing the risk of surgical rescue or a poor or deteriorated clinical outcome at 90 days.
Stroke Early Career Debate
Larry Goldstein, MD, Irving Jesus Reyes Barragan, Vivian Yang, MD, and Rajat Dhar, MD talk about their experience participating in the first ever Stroke Early Career Debate during the International Stroke Conference 2026 in New Orleans.
LAIS
Loberamisal for Acute Ischaemic Stroke (LAIS): A multicenter, randomized, double-blind, parallel, placebo-controlled phase 3 clinical trial
Shuya Li | Beijing Tiantan Hospital
RESULTS: When administered within 48 hours of AIS, loberamisal was associated with a 13% absolute increase in the proportion of adults achieving excellent functional outcomes at 90 days, with a favorable safety profile, compared to placebo.
Endovascular Treatment of Medium Vessel Occlusion Strokes with Moderate or Higher Clinical Severity
Raul G Nogueira | University of Pittsburgh, Pittsburgh, PA
RESULTS: Administering endovascular thrombectomy within 24 hours of symptom onset significantly improved 90-dayfunctional outcomes in patients with MeVO stroke compared to standard care alone, without increasing mortality or symptomatic intracranial hemorrhage.
ISC26 Conference Wrap Up
Program Chair Lauren Sansing, MD, MS, FAHA and Vice-chair Bijoy Menon, MBBS, MD, Msc, FRCPC review some of the top late-breaking science presented during the meeting and encourage viewers to attend the International Stroke Conference next year, February 10–12, 2027 in Houston, Texas.